Previous 10 | Next 10 |
BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that on May ...
Boca Raton, FL, May 18, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that David Moss, Chief Financial Officer will present a corp...
XPro™ Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improving Macrophage Phagocytosis (clearing) of Myelin Debris Data to be Presented on May 10, 2022, During the Best Abstract Presentations Session. Presen...
INmune Bio, Inc. (INMB) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Chairman and Chief Executive Officer CJ Barnum – Head of Neuroscience Conference Call Participants William Wo...
Image source: The Motley Fool. INmune Bio, Inc. (NASDAQ: INMB) Q1 2022 Earnings Call May 05, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: INmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript
INmune Bio press release (NASDAQ:INMB): Q1 GAAP EPS of -$0.39. Revenue of $0.2M. For further details see: INmune Bio GAAP EPS of -$0.39, revenue of $0.2M
Company Dosed First Phase 2 Mild Alzheimer’s Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell Treatment Effective Against Solid Malignancies $66.7 Million in cash as of March 31, 2022 Company to Host...
INmune Bio (NASDAQ:INMB) is scheduled to announce Q1 earnings results tomorrow, May 5, after market close. The consensus EPS estimate is -$0.60 and consensus revenue estimate is $0M. For further details see: INmune Bio Q1 2022 Earnings Preview
Boca Raton, Florida, April 28, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it...
Oxidative stress contributes to the formation of misfolded amyloid and tau proteins and to neuroinflammation all of which can further increase oxidative stress. Drugs that target pro-inflammatory cytokines such as INmune Bio's XPro1595 and Montelukast are likely too specific and too l...
News, Short Squeeze, Breakout and More Instantly...
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...
2024-06-12 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual r...